Granulocytapheresis Is Useful as an Alternative Therapy in Patients with Steroid-refractory or -dependent Ulcerative Colitis

Background:Recently, granulocyte and monocyte adsorption apheresis (GCAP) has been shown to be safe and effective for active ulcerative colitis (UC). We analyzed the safety and efficacy of GCAP (G-1 Adacolumn) in patients with steroid-refractory and -dependent UC. G-1 Adacolumn is filled with cellulose acetate carriers that selectively adsorb granulocytes and monocytes/macrophages. Methods:Forty-four patients with UC were treated with GCAP. These patients received 5 apheresis sessions over 4 weeks. Twenty patients had steroid-refractory UC (group 1) and 10 had steroid-dependent UC (group 2). Fourteen patients who did not want re-administration of steroids were treated with GCAP at the time of relapse, just after discontinuation of steroid therapy (group 3). Results:Of 44 patients treated with GCAP, 24 (55%) obtained remission (CAI ≤ 4), 9 (20%) showed a clinical response, and 11 (25%) remained unchanged. Only 2 of 10 patients (20%) with severe steroid-refractory UC (CAI ≥ 12) achieved remission, whereas 7 of 10 patients (70%) with moderate steroid-refractory UC achieved remission (p < 0.05). The dose of corticosteroids was tapered in 9 of 10 (90%) patients with steroid-dependent UC after GCAP therapy. Twelve (86%) of 14 patients in group 3 showed an improvement in symptoms and could avoid re-administration of steroids after GCAP. No severe adverse effects occurred. Conclusions:The findings of this study suggest that GCAP may be a useful alternative therapy for patients with moderate steroid-refractory or -dependent UC, although cyclosporin A or colectomy is necessary in patients with severe UC. GCAP may also be useful for avoiding re-administration of steroids at the time of relapse. Randomized, controlled clinical trials are needed to confirm these findings.

[1]  A. Saniabadi,et al.  Granulocytapheresis in the treatment of patients with rheumatoid arthritis. , 2008, Artificial organs.

[2]  I. Bjarnason,et al.  Adacolumn, an Adsorptive Carrier Based Granulocyte and MonocyteApheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with Leukocytes , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[3]  T. Yoshikawa,et al.  Immunomodulatory Effects of Granulocyte and Monocyte Adsorption Apheresis as a Treatment for Patients with Ulcerative Colitis , 2002, Digestive Diseases and Sciences.

[4]  P. Venge,et al.  IL-5 and TNF-α Participate in Recruitment of Eosinophils to Intestinal Mucosa in Ulcerative Colitis , 2001, Digestive Diseases and Sciences.

[5]  R. Cohen,et al.  Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? , 2001, Gastroenterology.

[6]  F. Shanahan,et al.  Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. , 2001, Gastroenterology.

[7]  A. Zinsmeister,et al.  Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy , 2000, American Journal of Gastroenterology.

[8]  S. Targan,et al.  Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis , 2000, American Journal of Gastroenterology.

[9]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[10]  R. William,et al.  Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. , 2000, Shock.

[11]  R. Cohen,et al.  A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. , 1999, Inflammatory bowel diseases.

[12]  W. Stack,et al.  Short‐ and long‐term outcome of patients treated with cyclosporin for severe acute ulcerative colitis , 1998, Alimentary pharmacology & therapeutics.

[13]  R. Kasukawa,et al.  A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. , 1998, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[14]  S. Edwards,et al.  Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. , 1997, Immunology today.

[15]  W. Sandborn.  A Critical Review of Cyclosporine Therapy in Inflammatory Bowel Disease , 1995 .

[16]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[17]  K. Batts,et al.  Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. , 1993, The American journal of gastroenterology.

[18]  Tamaki Yamada,et al.  Neutrophils, Nitrogen Oxides, and Inflammatory Bowel Disease a , 1992, Annals of the New York Academy of Sciences.

[19]  D. Rampton,et al.  Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease , 1991, Clinical and experimental immunology.

[20]  D. Present,et al.  Preliminary report: cyclosporin in treatment of severe active ulcerative colitis , 1990, The Lancet.

[21]  D. Jewell,et al.  Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. , 1986, Gut.

[22]  G. Järnerot,et al.  Intensive intravenous treatment of ulcerative colitis. , 1985, Gastroenterology.

[23]  A. Lilienfeld,et al.  Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. , 1981, Gastroenterology.

[24]  S. Truelove,et al.  FURTHER EXPERIENCE IN THE TREATMENT OF SEVERE ATTACKS OF ULCERATIVE COLITIS , 1978, The Lancet.

[25]  B. Hammer,et al.  Macrophage turnover in Crohn's disease and ulcerative colitis. , 1978, Gastroenterology.

[26]  A. McKendrick,et al.  DENTAL CARIES AND SUGAR INTAKE , 1975, The Lancet.

[27]  G. Weissmann.  Lysosomal mechanisms of tissue injury in arthritis. , 1972, The New England journal of medicine.

[28]  J. Fujimori,et al.  Improvement in rheumatoid arthritis following application of an extracorporeal granulotrap column, G-1 , 2004, Rheumatology International.

[29]  A. Munakata,et al.  Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter study , 2001, Journal of clinical apheresis.

[30]  Y. Mahida,et al.  The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. , 2000, Inflammatory bowel diseases.

[31]  A. Røseth,et al.  Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. , 1999, Scandinavian journal of gastroenterology.

[32]  M. Nagashima,et al.  Granulocyte and monocyte apheresis suppresses symptoms of rheumatoid arthritis: a pilot study , 1998, Rheumatology International.

[33]  M. Cassatella.  The production of cytokines by polymorphonuclear neutrophils. , 1995, Immunology today.

[34]  J. Goldberg,et al.  Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. , 1983, Gastroenterology.